Research Peptides | The Gillett Health Podcast #31

About this video

This short episode uses CJC-1295 as a cautionary example for research peptides marketed as anti-ageing or growth-hormone boosters. Gillett recounts that, according to his telling, a clinical trial in people with HIV-related visceral fat was stopped after a participant died following a heart attack, and he stresses the case was suspected to be unrelated but still illustrates hidden cardiac risk. He argues that raising growth hormone and IGF-1 substantially is not inherently desirable, because in his view growth signalling is linked to cancer-related pathways, and that benefit and risk often rise together with age. He advises minimum effective exposure and cardiac risk assessment rather than indefinite use.

Key takeaways

• A stopped trial story is used to argue research status should temper enthusiasm
• Gillett argues chronically high growth hormone and IGF-1 are not an anti-ageing goal in themselves
• Benefit and risk can rise together, especially in older adults he describes as more likely to benefit
• Long, continuous use of multiple peptides is presented as a pattern he counsels against
• Checking cardiac risk factors is framed as basic due diligence before growth-hormone approaches

Episode details: published March 30, 2023 · 2K views · 7:05 long. Summary written by Self Growth Videos from the episode itself. The hormone, metabolic and peptide concepts described are Dr. Kyle Gillett’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices. Disclosure: Gillett Health is a clinical practice that treats these conditions.

← Previous: Growth Hormone Peptides | The Gillett Health Podcast #31 · Next: Peptides for Cognitive Enhancement? | The Gillett Health Podcast #41 →

All Dr. Kyle Gillett videos · Dr. Kyle Gillett profile · Gillett Health (official site)